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Abstract
CD11b+Gr-1+ myeloid cells have gained much attention due to their roles in tumor immunity suppression as well
as promotion of angiogenesis, invasion, and metastases. However, the mechanisms by which CD11b+Gr-1+
myeloid cells recruit to the tumor site have not been well clarified. In the present study, we showed that hypoxia
could stimulate the migration of CD11b+Gr-1+ myeloid cells through increased production of macrophage
migration inhibitory factor (MIF) and interleukin-6 (IL-6) by head and neck squamous cell carcinoma (HNSCC)
cells. Hypoxia-inducible factor-1α (HIF-1α)– and HIF-2α–dependent MIF regulated chemotaxis, differentiation,
and pro-angiogenic function of CD11b+Gr-1+ myeloid cells through binding to CD74/CXCR2, and CD74/CXCR4
complexes, and then activating p38/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinases
(PI3K)/AKT signaling pathways. Knockdown (KD) of HIF-1α and HIF-2α in HNSCC cells decreased MIF level but failed
to inhibit the CD11b+Gr-1+ myeloid cell migration, because HIF-1α/2α KD enhanced nuclear factor κB (NF-κB)
activity that increased IL-6 secretion. Simultaneously blocking NF-κB and HIF-1α/HIF-2α had better inhibitory effect
on CD11b+Gr-1+ myeloid cell recruitment in the hypoxic zone than individually silencing HIF-1α/2α or NF-κB. In
conclusion, the interaction between HIF-α/MIF and NF-κB/IL-6 axes plays an important role in the hypoxia-induced
accumulation of CD11b+Gr-1+ myeloid cells and tumor growth in HNSCC.
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Introduction
A highly proliferating mass of tumor cells develops faster than the
vasculature, and tumor cells meet up with an avascular microenvi-
ronment deficient in oxygen, i.e., hypoxia [1]. The oxygen pressure
within solid tumors is heterogeneous, ranging from approximately
5% O2 in well-vascularized regions to anoxia near necrotic regions
but is, on average, in the hypoxic range (about 1% O2) [2]. Such
hypoxic zones have been postulated to be an incubator for malignant
evolution, where more aggressive cancer cells are selected. Hypoxia
induces numerous cellular adaptations during tumor progression,
including a switch to anaerobic metabolism, increased genetic insta-
bility, promotion of angiogenesis, activation of invasive growth, and
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preservation of the stemness. In addition, hypoxic tumor cells also
show increased resistance to radiotherapy and chemotherapy [1,3].
The major mechanisms mediating adaptive responses to hypoxia
are the stabilization and activation of the hypoxia-inducible factors
(HIFs), especially HIF-1α and HIF-2α. HIF-1α and HIF-2α trans-
activate a set of genes that facilitate tumor growth, angiogenesis, and
metastasis [4–6]. Although HIF-1α and HIF-2α have striking simi-
larities in structure, function, and regulation, many lines of evidence
suggest that these two HIF-α units play distinct and functionally
overlapping roles in the tumor progression [6].
Recently, much attention has been paid to a population of mye-
loid cells, identified by expressing the cell surface markers CD11b and
Gr-1 in mouse [7]. CD11b+Gr-1+ myeloid cells are a large group of
myeloid cells consisting of immature macrophages, granulocytes,
dendritic cells, and early myeloid progenitors [8]. CD11b+Gr-1+
myeloid cells are also termed myeloid-derived suppressor cells, related
to their ability to suppress tumor immunity and to impede cancer
immunotherapy [9]. In human, however, the corresponding cells
are inadequately characterized because of the lack of uniform markers.
In head and neck squamous cell carcinoma (HNSCC), it was reported
for the first time that CD34+ myeloid cells have immune suppressor
function in patients with HNSCC [10]. Since then, a growing body
of evidence suggests that level of circulating CD34+ myeloid cells is
correlated with lymph node metastasis and recurrence in patients
with HNSCC [11].
Clinical data showed that circulating myeloid-derived suppressor
cells correlated with cancer stage and metastatic tumor burden [12].
CD11b+Gr-1+ myeloid cells function by inhibiting CD4+ and
CD8+ T cell proliferation, by blocking natural killer cell activation, by
limiting dendritic cell maturation, and by polarizing immunity toward
a type 2 phenotype [13]. In addition, CD11b+Gr-1+ myeloid cells
have been implicated in a whole array of non-immunologic functions,
such as the promotion of angiogenesis, tumor cell invasion, and metas-
tases [14–17]. Despite the data defining the infiltration and functions
of CD11b+Gr-1+ myeloid cells in tumor progression, the molecular
mechanisms for their recruitment have not been well clarified.
More recently, Corzo et al. [8] demonstrated that hypoxia through
HIF-1α dramatically alters the functions of CD11b+Gr-1+ myeloid
cells in the tumor microenvironment and redirects their differentiation
toward tumor-associated macrophages. In addition, HIF-2αmodulated
the tumor-associated macrophage infiltration in murine hepatocellular
and colon carcinoma models through regulating the expression of
cytokine receptor macrophage colony-stimulating factor receptor
(M-CSFR) and the chemokine receptor CXCR4 [18]. Moreover,
Bv8 [19] and stromal-derived factor-1 (SDF-1) [20], which might be
related to hypoxia, are suggested to induce peripheral mobilization of
CD11b+Gr-1+ myeloid [19,21]. These results provided a mechanistic
link between CD11b+Gr-1+ myeloid cell function and hypoxic tumor
microenvironment.
Here, we demonstrate that hypoxia may stimulate the accumu-
lation of CD11b+Gr-1+ myeloid cells through increased production
of migration inhibitory factor (MIF) in HIF-1α/HIF-2α–dependent
ways. When HIF-1α/2α was artificially blocked, nuclear factor κB
(NF-κB)/interleukin-6 (IL-6) axis would be increased to com-
pensate for the loss of HIF-α/MIF under hypoxic condition. Simul-
taneously targeting HIF-α and NF-κB would be an attractive strategy
for inhibiting recruitment, differentiation, and pro-angiogenesis
of CD11b+Gr-1+ myeloid cells in hypoxic tumor microenvironment
of HNSCC.
Materials and Methods
Human and animal studies have been approved by the Institutional
Ethics Committee of State Key Laboratory of Oral Diseases, West
China Hospital of Stomatology, Sichuan University (Chengdu,
China). Detailed protocols are listed in the Supplementary Materials
and Methods.
shRNA Cloning, Lentivirus Packaging, and Stable Selection
Lenti-X shRNA Expression System (Clontech, Mountain
View, CA) was used for knocking down HIF-1α, HIF-2α, MIF,
and IL-6 as described previously [6]. Stable clones were selected
using 1.0 μg/ml puromycin.
Cell Culture, Hypoxia Treatment, and siRNA Transfection
Two human HNSCC cell lines Cal-27 and Tca8113 were cultured
under 20%O2 (normoxia) or 1%O2 (hypoxia) conditions, in a three-
gas incubator (Binder, Tuttlington, Germany). siRNAs were trans-
fected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA) at 30 nM.
Xenograft Tumor Model and Treatments
Cells were injected subcutaneously [s.c.; 5 × 106 cells/200 μl
phosphate-buffered saline (PBS) per mouse] on the back of nude mice.
Tumor size was calculated by πls2/6 (l = long side, s = short side).
Flow Cytometry Analyses
Single-cell suspension was incubated with fluorescence label anti-
bodies and analyzed on a Cytomics FC 500 MPL Flow Cytometer
(Beckman Coulter, Brea, CA) using RXP software (Beckman Coulter).
Data were analyzed using WinMDI 2.9 software.
Immunofluorescence and Immunohistochemistry
To detect the CD11b+Gr-1+ myeloid cells, frozen sections were
incubated with rabbit anti-mouse CD11b (1:50; NOVUS, Littleton,
CO) and rat anti-mouse Gr-1 (1:50; eBioscience, San Diego, CA)
and with secondary Alexa Fluor 488 goat anti-rabbit IgG (1:500;
Invitrogen) and DyLight 594 goat anti-rat IgG (1:500; Jackson,
Newmarket, United Kingdom). To detect the blood vessel, sections
were stained with primary rat anti-mouse CD31 (1:50; eBioscience)
and with secondary DyLight 594 goat anti-rat IgG (Jackson). The
formalin-fixed paraffin-embedded sections were stained with rabbit
anti–Ki-67 (1:50; Santa Cruz Biotechnology, Dallas, TX), biotinylated
goat anti-rabbit IgG, and streptavidin-peroxidase.
CD11b+Gr-1+ Myeloid Cell Sorting
Spleen cells were incubated with anti-mouse fluorescein isothio-
cyanate (FITC)–CD11b and phycoerythrin (PE)–Gr-1 (eBioscience).
CD11b+Gr-1+ and CD11b−Gr-1 cells were sorted with a MoFlo
XDP cell sorter (Beckman Coulter).
Chemotaxis
CD11b+Gr-1+ myeloid cells were seeded onto the top chamber
of a transwell insert (3 μM; Corning, Corning, NY) and were placed
in a 24-well plate that contains cytokines or tumor-conditioned
media. Migrated CD11b+Gr-1+ myeloid cells were stained by
0.1% crystal violet, followed by cell lysis, and measurement of optical
density at 540 nm. Recombinant human IL-6 (1 μg/ml; R&D Systems,
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Minneapolis, MN), recombinant humanMIF (rhMIF, 1 μg/ml; R&D
Systems), recombinant human PAI-1 (1 μg/ml; Millipore, Darmstadt,
Germany), and recombinant human intercellular adhesion molecule 1
(ICAM-1, 0.5 μg/ml; eBioscience) were used.
Cytokine Array and ELISA
Cytokines in the supernatant were measured using Human Cyto-
kine Array Kit (R&D Systems). Membranes were scanned by a den-
sitometer (Bio-Rad Laboratories, Hercules, CA). Interested cytokines
were further validated by ELISA using Quantikine ELISA Kit (R&D
Systems). The intensity was measured at 450 nm in a microplate reader
(Thermo, Waltham, MA).
Quantitative Real-Time Reverse Transcription–Polymerase
Chain Reaction and Western Blot
Polymerase chain reaction (PCR) amplification was performed
using Thunderbird SYBR qPCR mix (TOYOBO, Osaka, Japan) on
an ABI PRISM 7300 System (Applied Biosystems, Foster City, CA).
Protein were separated on 8% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and sequentially stained with primary antibodies
and HRP-labeled secondary antibodies. Bands were scanned using a
densitometer (GS-700; Bio-Rad Laboratories).
Luciferase Reporter Assay
Cells were transfected with pNF-κB–luc vector (Clontech) and
pRL-TK Vector (Promega) using the Lipofectamine 2000 (Invitrogen)
and then were lysed and assayed using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI). Luciferase activity was mea-
sured in a luminometer. Results are expressed as relative NF-κB activity
compared with controls after normalizing to Renilla luciferase activity.
CXCR Internalization Assays
CD11b+Gr-1+ myeloid cells were treated with buffer, MIF, and
MIF plus anti-CD74, respectively, and were washed with acidic glycine
buffer. Then, these cells were stained with antibodies to CXCR2 or
CXCR4 and were analyzed by flow cytometry.
Statistics
Comparisons of means among groups were analyzed by one-way
analysis of variance (ANOVA), and mean tumor volume was ana-
lyzed by repeated measures ANOVA. The Bonferroni test was fur-
ther used to determine the differences between groups. The
correlations between CD34+ myeloid cell frequency and the clinical-
pathologic characteristics of patients were analyzed by Pearson χ2 test.
All statistical analyses were performed using SPSS 13.0. P < .05 was
considered statistically significant.
Results
Expansion of CD11b+Gr-1+ Myeloid Cells in Tumor-Bearing
Mice Promoted the Growth and Angiogenesis of Tumor
The expansion of CD11b+Gr-1+ myeloid cells was well described
in immunocompetent mice due to their role in suppressing host
immunity and impeding cancer immunotherapy [9]. In immuno-
deficient mice, however, whether CD11b+Gr-1+ myeloid cells
would be induced by tumors has not been fully elucidated. We
therefore investigated whether CD11b+Gr-1+ myeloid cells would
be expanded in the immunodeficient nude mice bearing HNSCC.
Two HNSCC cell lines, Cal-27 and Tca8113, were s.c. injected to
nude mice. Four weeks later, CD11b+Gr-1+ myeloid cells in spleens
and peripheral blood were analyzed by flow cytometry. The percent-
age of CD11b+Gr-1+ myeloid cells in the spleens of tumor-free mice
varied from 3.2% to 5.7% (mean = 4.24%, n = 5), while that in the
tumor-bearing mice varied from 9.5% to 12.7% (mean = 11.12%, n =
5). The percentage of CD11b+Gr-1+ myeloid cells in spleens of tumor-
bearing mice was significantly increased in comparison with tumor-free
mice for both cell lines (P < .001; Figure 1A). Similarly, the percentage
of CD11b+Gr-1+ myeloid cells in peripheral blood of tumor-bearing
mice (23.5%-28.4%, mean = 25.8%, n = 5) was significantly (P < .001;
Figure 1A) increased compared with tumor-free mice (9.5%-12.6%,
mean = 10.8%, n = 5). In human, CD34+ immune suppressive mye-
loid cells are similar to the murine CD11b+Gr-1+ myeloid cells
[10,22]. To validate the data in nude mice, we measured the CD34+
immune suppressive myeloid cells in the peripheral blood from 48 pa-
tients with HNSCC and 10 healthy volunteers using flow cytometry.
The percentage of CD34+ myeloid cells in patients (7.47%-22.5%,
mean = 15.54%) was significantly higher (P < .001) than that in
healthy volunteers (4.3%-16.3%, mean = 10.21%; Figure 1B). The
animal model and human data support the notion that CD11b+Gr-1+
myeloid cells would be expanded by HNSCC.
To study the function of CD11b+Gr-1+ myeloid cells in HNSCC-
bearing nude mice, we sorted CD11b+Gr-1+ and CD11b−Gr-1−
subpopulations from spleens of tumor-bearing mice using
FACS. The purification of sorted CD11b+Gr-1+ myeloid cells was
89.27% as analyzed by flow cytometry (Figure W1). Cal-27 cells
(4 × 106 cells), admixedwithCD11b+Gr-1+myeloid cells (1 × 106 cells)
or CD11b−Gr-1− cells (1 × 106 cells), respectively, were injected s.c.
on the back of nude mice. The tumor size was monitored weekly.
Tumors admixed with CD11b+Gr-1+ myeloid cells had significant
larger volume and weight than that admixed with CD11b−Gr-1−
cells (Figure 1C ). The proliferation rate of tumor was measured
by immunohistochemical staining of the proliferation marker Ki-67.
In accordance with the growth curve, Ki-67–positive rate in the tumors
admixed with CD11b+Gr-1+ myeloid cells was significantly higher
than that admixed with CD11b−Gr-1− cells (P = .005; Figure 1D).
Since nude mice lack thymus and unable to produce mature T cells,
there should be more mechanisms, other than immune suppression,
by which CD11b+Gr-1+ myeloid cells promote xenograft tumor
growth in nude mice. Recently, CD11b+Gr-1+ myeloid cells were
found to render tumors refractory to anti–vascular endothelial growth
factor (VEGF) treatment [23] and contribute to the tumor angiogenesis
[15,19,24]. We therefore measured the microvessel density (MVD) of
xenograft tumors supplementedwith CD11b+Gr-1+ or CD11b−Gr-1−
cells. As shown in Figure 1E , the CD11b+Gr-1+ myeloid cell supple-
mentation significantly increased the MVD (P = .004). These results
indicate that CD11b+Gr-1+myeloid cells may contribute to the growth
of tumor through stimulating proliferation and angiogenesis.
MIF and IL-6 Mediated Hypoxic Chemotaxis of CD11b+Gr-1+
Myeloid Cells in HNSCC
Since hypoxia is a common feature of solid tumor, we sought to
investigate whether hypoxic microenvironment would recruit more
CD11b+Gr-1+ myeloid cells to the hypoxic tumor zone. Initially,
we sorted CD11b+Gr-1+ myeloid cells from spleens of tumor-bearing
mice using FACS and seeded cells in cell culture insets. Supernatants
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of normoxia- and hypoxia-treated cancer cells were added onto the
lower wells and incubated for 6 hours. Compared with tumor-free
medium, supernatant of normoxic cancer cells significantly increased
the migration of CD11b+Gr-1+ myeloid cells (Figure 2A; Tca8113:
P = .003; Cal-27: P = .018). The supernatant of hypoxia-treated
cancer cells further increased the number of migrated CD11b+Gr-1+
myeloid cells in comparison with normoxic cancer cells (Figure 2A;
Tca8113: P < .001; Cal-27: P = .001). We then measured the
CD11b+Gr-1+ myeloid cells in xenograft tumors using immuno-
fluorescence staining. CD11b+Gr-1+ myeloid cells were detected
in the xenograft tumor, and interestingly, these cells tended to accu-
mulate around the necrotic zone (Figure 2B). Since the area around
the necrotic zone is suggested to be hypoxic [1], these results, com-
bined with in vitro chemotaxis assay, indicate that hypoxic micro-
environment may promote the chemotaxis of CD11b+Gr-1+ myeloid
cells in HNSCC.
Several tumor-secreted cytokines have been suggested to induce
CD11b+Gr-1+ myeloid cell migration. We measured the cytokines
in supernatant of cancer cells using a human cytokine array kit. MIF,
IL-6, sICAM-1, and PAI-1 were detected in the normoxic super-
natants and were increased in the hypoxic condition (Figure 2C ).
Quantitative analysis using ELISA confirmed these results in both
HNSCC cell lines (Figure W2). We next investigated whether these
hypoxia-induced factors, MIF, IL-6, sICAM-1, and PAI-1, could
regulate the chemotaxis of CD11b+Gr-1+ myeloid cells. Recom-
binant sICAM-1, PAI-1, and siRNAs targeting sICAM-1 and PAI-1
had no significant effect on the chemotaxis of CD11b+Gr-1+ myeloid
cells (Figure 2D, lower panel). Normoxic supernatants supplemented
with recombinant MIF (1 μg/ml, P < .001) and IL-6 (1 μg/ml, P <
.001) significantly increased the migration of CD11b+Gr-1+ myeloid
cells by 2.33-fold and 1.65-fold, respectively (Figure 2D, upper
panel ). In addition, supernatant from MIF (P < .001) and IL-6
(P = .001) knockdown (KD) tumor cells that were cultured under
hypoxia had significantly decreased migration of CD11b+Gr-1+
myeloid cells than that from control cells (Figure 2D, upper panel ).
The silencing efficiency of siRNAs was shown in Figure W3.
To evaluate the in vivo effects of IL-6 and MIF on CD11b+Gr-1+
myeloid cell recruitment, IL-6 and MIF in cancer cells were stably
knocked down by lentiviral shRNAs. MIF KD or IL-6 KD cells were
s.c. injected into nude mice. Four weeks later, the infiltration of
CD11b+Gr-1+ myeloid cells in tumors was significantly reduced by
both MIF KD (3.9% ± 1.2%, P < .001) and IL-6 KD (5.6% ± 1.3%,
Figure 1. Expansion of CD11b+Gr-1+myeloid cells in tumor-bearing mice promotes tumor growth and angiogenesis. (A) Representative
images of flow cytometry analysis for frequencies of CD11b+Gr-1+myeloid cells in spleens and peripheral blood. Two HNSCC cell lines,
Cal-27 and Tca8113, were injected s.c. on the back of nude mice. Four weeks later, the frequency of CD11b+Gr-1+ myeloid cells in
spleens and peripheral blood was analyzed by flow cytometry. Tumor-bearing mice had significant higher percentage of CD11b+Gr-1+
myeloid cells in both spleens and peripheral blood (n = 5, P < .001). (B) CD34+ myeloid cells in the peripheral blood of healthy volunteers
and patients with HNSCC. Upper panel: Representative images of flow cytometry analysis of CD34+ myeloid cells. Lower panel: Quanti-
tative data. In comparison with healthy volunteers, patients with HNSCC have significantly higher frequency of CD34+ myeloid cell in the
peripheral blood. Central solid line:median, box:middle 50%of data, error bar cap lines: 10th and 90th percentiles (*P< .001). (C) Cal-27 cells
admixedwith CD11b+Gr-1+ cells or CD11b−Gr-1− cells were injected s.c. on the back of nudemice. Tumors admixedwith CD11b+Gr-1+
cells had significant larger volume (left panel) and weight (right panel) than that admixed with CD11b−Gr-1− cells (n = 5, *P < .05).
(D) Proliferation rate of tumor was measured by immunohistochemical staining of the proliferation marker Ki-67. The Ki-67–positive
rate in the tumors admixed with CD11b+Gr-1+ cells was significantly higher than that admixed with CD11b−Gr-1− cells (n = 5, *P < .05,
inset: 400×, bar: 50 μm). (E) Blood vessels in the tumor were detected by immunohistochemical staining of CD31. MVD was evaluated
by amicroscope. Tumors admixedwith CD11b+Gr-1+myeloid cells had significantly higherMVD than that with CD11b−Gr-1− cells (n=5,
*P < .05, bar: 50 μm).
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P < .001) measured by flow cytometry (Figure 2E ). These in vitro
and in vivo results suggest that hypoxia-induced IL-6 and MIF may
stimulate the chemotaxis of CD11b+Gr-1+ myeloid cells in tumor.
IL-6 was reported to regulate CD11b+Gr-1+ myeloid cell migra-
tion by previous studies [13,25], while MIF, however, has not been
well studied in the CD11b+Gr-1+ myeloid cell migration and
function. We therefore further focused on how MIF regulate the
chemotaxis of CD11b+Gr-1+ myeloid cells.
MIF/CD74/CXCR2/CXCR4 Complexes Mediated Hypoxia-
Induced Migration of CD11b+Gr-1+ Myeloid Cells through
p38/MAPK and PI3K/AKT Signaling Pathways
Extracellular MIF can bind to the cell surface receptor CD74
that forms signaling complexes with G-protein–coupled chemokine
receptors (CXCR2 and CXCR4) to mediate MIF function [26,27].
We therefore detected the expression of CD74, CXCR2, and
CXCR4 expression in CD11b+Gr-1+ myeloid cells sorted from
Figure 2.MIF and IL-6 mediate hypoxic chemotaxis of CD11b+Gr-1+myeloid cells in HNSCC. (A) Supernatants of Tca8113 and Cal-27
cells were added onto the lower wells, and CD11b+Gr-1+ myeloid cells were seeded on the upper chamber of a transwell assay.
Compared with tumor-free medium, supernatant of normoxic (20% O2) cancer cell significantly increased the chemotaxis of CD11b
+Gr-1+myeloid cells. The supernatant of hypoxia-treated (1% O2) cancer cells further increased the number of migrated CD11b+Gr-1
+ myeloid cells in comparison with normoxic cells. Experiments were carried out in triplicate (*P < .05). (B) Representative images
of immunofluorescence staining of Gr-1 (green) and CD11b (red) in a xenograft tumor. Necrotic zone was marked by a dashed line.
CD11b+Gr-1+ myeloid cells tend to accumulate around the necrotic zone (bar: 50 μm). (C) Cytokines in the supernatant of normoxic and
hypoxic cancer cells were measured using human cytokine array kit. (D) Role of MIF (upper left), IL-6 (upper right), sICAM-1 (lower left), and
PAI-1 (lower right) on the chemotaxis of CD11b+Gr-1+ myeloid cells. Recombinant cytokines or supernatants from siRNA-treated cancer
cellswere added on the lower chamber. IL-6 andMIF increased the chemotaxis of CD11b+Gr-1+myeloid cells,while sICAM-1 andPAI-1 had
nothing to dowithCD11b+Gr-1+myeloid cell chemotaxis. Experimentswere carried out in triplicate (*P< .05). (E) Left panel: Representative
flow cytometry analysis of CD11b+Gr-1+myeloid cells in the tumor site. Right panel: Quantitative analysis of the flow cytometry data. MIF
and IL-6 KD significantly impaired the recruitment of CD11b+Gr-1+ myeloid cells in the tumor site (n = 5, *P < .05, **P < .001).
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spleens of tumor-bearing mice. Western blot showed that CD74,
CXCR2, and CXCR4 were expressed in the CD11b+Gr-1+ myeloid
cells (Figure 3A). We further investigated whether MIF regulated
CD11b+Gr-1+ myeloid cell chemotaxis through interacting with
CD74/CXCR2 and CD74/CXCR4 complexes. CD11b+Gr-1+
myeloid cells were seeded in cell culture insets. rhMIF was added
into the lower wells with or without neutralizing anti-mouse CD74,
CXCR2, and CXCR4, respectively. The neutralization of CD74,
CXCR2, and CXCR4 significantly decreased the migration of
CD11b+Gr-1+ myeloid cells (Figure 3B). To further confirm the
binding of MIF to CXCR2 and CXCR4, we used an internalization
assay that reports specific receptor-ligand interactions. Flow cytom-
etry analysis of surface CXCR2 and CXCR4 on CD11b+Gr-1+
myeloid cells showed that MIF induced internalization of both
CXCR2 and CXCR4. The internalization of CXCR2 and CXCR4
was attenuated by anti-CD74 antibody treatment. These results indi-
cate that MIF stimulate the migration of CD11b+Gr-1+ myeloid cells
through interacting with CD74/CXCR2 and CD74/CXCR4 com-
plexes (Figure 3C ).
It was reported that MIF modulates chemotaxis of neutrophil and
monocytes in inflammation models through activating intracellular
signaling pathways, such as p38/mitogen-activated protein kinase
(MAPK) and phosphatidylinositide 3-kinases (PI3K)/AKT signaling
pathways [28,29]. We therefore investigated whether MIF would
activate these pathways in CD11b+Gr-1+ myeloid cells. CD11b+Gr-1+
myeloid cells were stimulated with rhMIF for 15 minutes. After
rhMIF and hypoxic tumor supernatant treatment, levels of phosphor-
AKT and phosphor-p38 were significantly increased. However, such
increase was abrogated by anti-CD74 antibody and MIF antagonist
ISO-1 (Figure 3D). To test whether the increased phosphorylation of
Figure 3.MIF/CD74/CXCR2/CXCR4 complexes contribute to migration of CD11b+Gr-1+ myeloid cells through p38/MAPK and PI3K/AKT
signaling pathways. (A) Expression of CD74, CXCR4, and CXCR2 in the CD11b+Gr-1+ myeloid cells was measured by Western blot.
Protein samples from CD11b+Gr-1+ myeloid cells of two different mice were loaded. (B) CD11b+Gr-1+ myeloid cells were seeded in
cell culture insets. rhMIF was added into the lower wells with or without neutralizing anti-mouse CD74 (upper panel), CXCR4 (middle
panel), or CXCR2 (lower panel). The neutralization of CD74, CXCR2, and CXCR4 significantly decreased the migration of CD11b+Gr-1+
myeloid cells. Crtl IgG: Control IgG. Experiments were carried out in triplicate (*P < .05). (C) Internalization assay: Flow cytometry anal-
ysis of membrane CXCR2 and CXCR4 on CD11b+Gr-1+ myeloid cells. MIF induced internalization of both CXCR4 (upper panel) and
CXCR2 (lower panel). The internalization of CXCR2 and CXCR4 was attenuated by anti-CD74 antibody treatment. (D) The phosphorylation
of AKT and p38 in the CD11b+Gr-1+ myeloid cells measured by Western blot. After a 15-minute treatment with rhMIF and hypoxia
tumor supernatant (hypoxic SU), the levels of p-AKT and p-38 were significantly increased. In the presence of anti-CD74 neutralizing
antibody or ISO-1, the increase in phosphorylation was attenuated. (E) CD11b+Gr-1+ myeloid cells were treated, respectively, with PI3K
inhibitor and p38 inhibitor for 1 hour before stimulating with rhMIF. PI3K inhibitor and p38 inhibitor significantly decreased rhMIF-
induced migration of CD11b+Gr-1+ myeloid cells by 33% and 40%, respectively. Experiments were carried out in triplicate (*P < .05).
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PI3K/AKT and p38/MAPK contributes to increased CD11b+Gr-1+
myeloid cell chemotaxis, CD11b+Gr-1+ myeloid cells were treated,
respectively, with PI3K inhibitor and p38 inhibitor for 1 hour before
stimulating with rhMIF. PI3K inhibitor and p38/MAPK inhibitor
significantly decreased rhMIF-induced CD11b+Gr-1+ myeloid cell
migration by 35% and 46%, respectively (Figure 3E ). These results
suggest that hypoxia-induced MIF stimulates the chemotaxis of
CD11b+Gr-1+ myeloid cells through activating PI3K/AKT and p38/
MAPK signaling pathways.
MIF Regulated Differentiation and Angiogenic Potential of
CD11b+Gr-1+ Myeloid Cells
We further investigated whether MIF could regulate the differen-
tiation and function of CD11b+Gr-1+ myeloid cells in HNSCC-
bearing nude mice. MIF KD cancer cells were s.c. injected to the nude
mice. Four weeks later, we examined the granulocytic (CD11b+
Ly6GhighLy6Clow) and monocytic (CD11b+Ly6GlowLy6Chigh) phe-
notypes in the xenograft tumors using flow cytometry. The percent-
age of monocytic phenotype in CD11b+ population was significantly
decreased in MIF KD tumors in comparison with control tumors
(Figures 4A and W4). To study the effect of MIF on CD11b+Gr-1+
myeloid cell differentiation in vitro, CD11b+Gr-1+ myeloid cells
were sorted from tumor-bearing nudemice and were cultured for 5 days
in the presence of granulocyte-macrophage–colony-stimulating factor
(GM-CSF). During the period of culture, cells were treated with
recombinant MIF, tumor supernatant, or ISO-1. MIF, normoxic
tumor supernatant, and hypoxic tumor supernatant induced differ-
entiation of CD11b+Gr-1+ myeloid cells into monocytic phenotype
(Figure 4B). Moreover, hypoxic tumor supernatant–treated CD11b
+Gr-1+ myeloid cells had higher percentage of monocytic phenotype
than that of normoxic tumor supernatant. In the presence of ISO-1,
the induction ofmonocyticCD11b+Gr-1+myeloid cells was eliminated
(Figure 4B). These in vivo and in vitro data suggest that hypoxia-
inducedMIFmay redirect the differentiation of CD11b+Gr-1+myeloid
cells toward monocytic phenotype.
As mentioned above that supplement of CD11b+Gr-1+ myeloid
cells increased MVD, we investigated the role of MIF on the MVD
of the tumor. MIF KD tumors have decreased MVD compared
with control tumors (Figure 4C ). To study whether MIF could
regulate the production of VEGF, CD11b+Gr-1+ myeloid cells
were treated with rhMIF, ISO-1, PI3K inhibitor, or p38 inhibitor,
respectively. VEGF in the supernatant was measured by ELISA.
MIF significantly increased the production of VEGF by CD11b
+Gr-1+ myeloid cells. ISO-1 attenuated the induction effects of
rhMIF on VEGF expression. Moreover, the VEGF level was de-
creased by PI3K inhibitor and p38 inhibitor (Figure 4D). These
results suggest that MIF may stimulate the angiogenic property
Figure 4.MIF regulates differentiation and angiogenic potential of CD11b+Gr-1+ myeloid cells. (A) Granulocytic (CD11b+Ly6GhighLy6Clow)
and monocytic (CD11b+Ly6GlowLy6Chigh) phenotypes in the xenograft tumors were analyzed by flow cytometry. The percentage of mono-
cytic phenotype in CD11b+ population was significantly decreased in MIF KD tumors in comparison with control tumors (n = 5, *P <
.05). (B) CD11b+Gr-1+ cells were sorted from tumor-bearing nude mice and cultured for 5 days in the presence of GM-CSF. Cells were
treated with rhMIF, ISO-1, and normoxic or hypoxic tumor supernatant (Su). Granulocytic and monocytic phenotypes were analyzed by
flow cytometry. MIF, normoxic tumor supernatant, and hypoxic tumor supernatant increased the percentage of monocytic cells. ISO-1 sig-
nificantly inhibited the induction of monocytic phenotype. Experiments were carried out in triplicate (*P < .05). (C) Immunofluorescence
staining of CD31 in the xenograft tumor, and MVD was calculated under a microscope. The MVD in MIF KD tumor and ISO-1–treated
tumor was significantly decreased (bar: 50 μm, n = 5, *P < .05). (D) Protein levels of VEGF in the supernatant of CD11b+Gr-1+
myeloid cells were measured by ELISA. MIF significantly increased the production of VEGF by CD11b+Gr-1+ cells. ISO-1, PI3K inhibitor,
and p38 inhibitor significantly decreased MIF-induced production of VEGF by CD11b+Gr-1+ cells.
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of CD11b+Gr-1+ myeloid cells through activating PI3K/AKT and
p38/MAPK signaling pathways.
HIF-α/MIF and NF-κB/IL-6 Axes Co-Regulated the
Migration of CD11b+Gr-1+ Myeloid Cells under Hypoxia
HIFs are critical factors in regulating hypoxia adaptation and
function [1,5]. We therefore cultured HIF-1α KD and HIF-2α
KD HNSCC cells under hypoxic condition and collected the super-
natant for cytokine array and CD11b+Gr-1+ myeloid cell chemotaxis
assay. The knocking down efficiency of HIF-1α and HIF-2α was
shown in Figure W5A. MIF level was significantly decreased by
knocking down HIF-1α and HIF-2α measured by both cytokine array
(Figure 5A) and ELISA (Figure W5B), indicating that hypoxic induc-
tion of MIF is regulated by both HIF-1α and HIF-2α in HNSCC cells.
To further study the effects of HIF-1α and HIF-2α on the chemotaxis
of CD11b+Gr-1+ myeloid cells, supernatant from hypoxia-treated
HIF-1α KD and HIF-2α KD HNSCC cells was used for chemotaxis
assay. The migration of CD11b+Gr-1+ myeloid cells was not signifi-
cantly decreased by knocking down HIF-1α or HIF-2α (Figure 5B).
We showed above that MIF, as a common target of HIF-1α and
HIF-2α, contributed to the chemotaxis of CD11b+Gr-1+ myeloid
cells (Figure 2D). However, HIF-1α and HIF-2α KD did not signif-
icantly affect the migration of CD11b+Gr-1+ myeloid cells. There-
fore, there should be some other mechanisms that compensated for
the lost of MIF after HIF-1α and HIF-2α KD contribute to the migra-
tion of CD11b+Gr-1+ myeloid cells. When looked back into the cyto-
kine array data, we noticed that HIF-1α and HIF-2α KD decreased
the level of MIF, while increased the level of IL-6, IL-8, CXCL10,
and CCL5 (Figure 5A). The increase of these cytokines was validated
by ELISA (Figure W5C ).
Interestingly, IL-6, IL-8, CXCL10, and CCL5 are all reported as
targets of NF-κB [30]. We confirmed this in HNSCC cell lines by
p65 shRNA that significantly inhibited the levels of IL-6, IL-8,
CXCL10, and CCL5 in both HNSCC cell lines (Figure W5D).
We therefore hypothesized that the increase of IL-6, IL-8, CXCL10,
Figure 5. HIF-α/MIF and NF-κB/IL-6 axes co-regulate the migration of CD11b+Gr-1+ myeloid cells under hypoxia. (A) Cytokines in the
supernatant of control shRNA-transfected (ctrl shRNA), HIF-1α KD, and HIF-2α KD tumor cells were measured using a human cytokine
array kit. (B) Supernatant from control shRNA-transfected (Ctrl shRNA), HIF-1α KD, and HIF-2α KD tumor cells were applied for chemo-
taxis assay. Neither HIF-1α nor HIF-2α KD reduced the migration of CD11b+Gr-1+ myeloid cells. Experiments were carried out in trip-
licate. (C) NF-κB activity was measured using NF-κB luciferase reporter assay. The NF-κB activity was significantly increased by HIF-1α
and HIF-2α KD under hypoxia. Experiments were carried out in triplicate (*P < .05). (D) NF-κB activity in tumor cells was inhibited by
siRNA targeting p65, PDTC, or BAY-11-7082. Then, supernatant of tumor cells was applied for chemotaxis assay of CD11b+Gr-1+
myeloid cells. CD11b+Gr-1+ myeloid cell migration was significantly inhibited by siRNA targeting p65, PDTC, or BAY-11-7082. Experi-
ments were carried out in triplicate (*P< .05). (E) Combined silencing of NF-κB and HIF-1α/2α decreased the CD11b+Gr-1+ myeloid cell
migration more than silencing NF-κB individually. Experiments were carried out in triplicate (*P < .05, **P < .001). (F) The frequency of
CD11b+Gr-1+ myeloid cells in the xenograft tumors was measured by flow cytometry. Simultaneously targeting NF-κB and HIF-1α/2α
had better inhibitory effect on the recruitment of CD11b+Gr-1+ myeloid cells in the tumor than targeting NF-κB and HIF-1α/2α individ-
ually (n = 5, *P < .05, **P < .001).
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and CCL5 after HIF-1α and HIF-2α KD may be attributed to an
increase of NF-κB activity. We measured NF-κB activity using NF-κB
luciferase reporter assay. Hypoxia stimulated a 1.95 ± 0.26-fold increase
in NF-κB luciferase activity (P = .005; Figure 5C ). The NF-κB–
dependent transcriptional activity was further significantly increased
by HIF-1α (P = .005) and HIF-2α KD (P = .013; Figure 5C). These
results support the hypothesis that NF-κB activity was increased by
HIF-1α and HIF-2α KD.
We next investigated whether NF-κB contributed to the migration
of CD11b+Gr-1+ myeloid cells in vitro. shRNAs targeting p65 and
two NF-κB inhibitors, PDTC and BAY-11-7082, were used to inhibit
the NF-κB activity in HNSCC cells. Supernatants were harvested and
applied for CD11b+Gr-1+ myeloid cell migration assay. The inhibition
of NF-κB pathway inhibited the hypoxic stimulation of CD11b+Gr-1+
myeloid cell migration (Figure 5D). Moreover, combined inhibition of
NF-κB and HIF-1α/HIF-2α decreased the CD11b+Gr-1+ myeloid
cell migration more than inhibition of NF-κB or HIF-1α/HIF-2α
individually (Figure 5E).
To validate this in vivo, p65 and HIF-1α/HIF-2α in HNSCC
were knocked down individually or simultaneously by lentiviral
shRNAs. Xenograft tumors were established by s.c. injecting the
stable infected cells to nude mice. Four weeks later, CD11b+Gr-1+
myeloid cells in the tumor were analyzed by flow cytometry. In
accordance with the in vitro data, there was a slight decrease of the
CD11b+Gr-1+ myeloid cells in the HIF-1α and HIF-2α KD tumors
compared with control shRNA tumors but did not quite achieve
significance (Figure 5F ; P > .05). The silence of p65 significantly
decreased the recruitment of CD11b+Gr-1+ myeloid cells in the tumor
(Figure 5F ; P < .05). Moreover, simultaneously knocking down p65
and HIF-1α/HIF-2α had better inhibitory effect on CD11b+Gr-1+
myeloid cell recruitment in the tumor than individually knocking
down HIF-1α/HIF-2α or p65 (Figure 5F ; P < .001). The volume
of xenograft tumor was monitored during the period of experiment.
Knocking down HIF-1α, HIF-2α, and NF-κB individually inhib-
ited the growth of tumor in comparison with the control group.
The growth of tumor was further decreased by combined KD of
HIF-1α/2α and NF-κB (Figure W6). These data indicate that
hypoxia HNSCC may induce the recruitment of CD11b+Gr-1+
myeloid cells mainly through increased production of MIF in
HIF-1α/2α–dependent ways. When HIF-1α/HIF-2α was artificially
inhibited, NF-κB/IL-6 axis would be strengthened to compensate
for the loss of HIF-α/MIF axis in regulating the recruitment of
CD11b+Gr-1+ myeloid cells (Figure 6).
Discussion
In the present study, we showed that CD11b+Gr-1+ myeloid cells
contributed to the growth and angiogenesis of HNSCC xenograft
tumor. Hypoxic microenvironment induced HNSCC cells to secrete
more MIF and IL-6, both of which could stimulate the recruitment
of CD11b+Gr-1+ myeloid cells. HIF-1α/2α–dependent MIF regu-
lates CD11b+Gr-1+ myeloid cell migration, differentiation, and pro-
angiogenic function through binding to CD74/CXCR2, and CD74/
CXCR4 complexes, and then activating p38/MAPK and PI3K/AKT
signaling pathways. KD of HIF-1α/2α decreased MIF but did not
inhibit the CD11b+Gr-1+ myeloid cell migration, because it increased
the level of IL-6 and CCL5 in an NF-κB–dependent way. Simul-
taneously silencing NF-κB and HIF-1α/HIF-2α had better inhibitory
effect on CD11b+Gr-1+ myeloid cell recruitment in the tumor than
individually knocking down HIF-1α/2α or NF-κB.
In this study, the athymic nude mice were used as host for the
establishment of human HNSCC xenograft. The immunodeficient
profiling of nude mouse makes it inappropriate for studying the
immune suppressive function of CD11b+Gr-1+ myeloid cells. How-
ever, on the other side, it would exclude the interference of immune
effect when studying the non-immunologic functions, i.e., angio-
genesis. In this study, we showed that cancer cells co-injected
with CD11b+Gr-1+ myeloid cells had higher MVD than that
Figure 6. Schematic cartoon illustrating how hypoxia regulates migration of CD11b+Gr-1+ myeloid cells. Hypoxia stimulates HNSCC
cells to produce more MIF in an HIF-1α/2α–dependent way. MIF regulates CD11b+Gr-1+ myeloid cell migration, differentiation, and pro-
angiogenic function through binding to CD74/CXCR2, and CD74/CXCR4 complexes, and then activating p38/MAPK and PI3K/AKT signaling
pathways. NF-κB/IL-6 axis would be an alternative to compensate for the loss of HIF-α/MIF in regulating the migration of CD11b+Gr-1+
myeloid cells when HIF-1α/2α were inhibited.
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with CD11b−Gr-1− myeloid cells. In addition, inhibiting MIF
decreased the recruitment of CD11b+Gr-1+ myeloid cells accom-
panied by decreased MVD and VEGF expression level. These
results, along with previous reports [15,16], suggest that the infil-
tration of CD11b−Gr-1− myeloid cells may contribute to the angio-
genesis of HNSCC.
Hitherto, there was no direct evidence to suggest that hypoxic
microenvironment could induce migration of CD11b+Gr-1+ mye-
loid cells in HNSCC. In the present study, we found that CD11b
+Gr-1+ myeloid cells tend to accumulate in the hypoxic zones in
HNSCC xenograft tumors and that supernatant of hypoxia-treated
HNSCC cells increased the CD11b+Gr-1+ myeloid cell migration
in vitro. These results provided a direct link between hypoxia and
migration of CD11b+Gr-1+ myeloid cells. We further measured
the cytokines in supernatant of HNSCC cells and found that
two cytokines, MIF and IL-6 secreted by HNSCC cells, were increased
by hypoxia and contributed to the hypoxia-induced CD11b+Gr-1+
myeloid cell migration. SDF-1 was also found to induce CD11b+Gr-1+
myeloid cell migration in human and murine mammary tumors
[14,20]. However, our data showed that SDF-1 is not an important
cytokine that mediated the chemotaxis of CD11b+Gr-1+ myeloid cells
by HNSCC cells. The reason may be that different types of cancer
express different cytokines and respond differently to hypoxia.
MIF was originally identified as a T cell–derived factor responsible
for the inhibition of macrophage migration in the mid-1960s. Exten-
sive studies since have revealed its pleiotropic roles in immune and
inflammatory responses [31,32]. Recently, a growing amount of
evidence supports the notion that MIF exhibits pro-neoplastic activ-
ities, including tumor suppressor down-regulation, cyclooxygenase-2
(COX-2) and prostaglandin E2 (PGE2) up-regulation, potent induc-
tion of angiogenesis and enhanced tumor proliferation, growth, and
invasiveness [32–35]. One of the most important among these is the
modulation of hypoxic adaptation within the tumor microenviron-
ment by interacting with HIF-1α [36]. Here, we showed that MIF
level was increased by hypoxia in HNSCC cells, and this increase of
MIF was abrogated by KD of either HIF-1α or HIF-2α, indicating
that HIF-1α and HIF-2α play similar roles in the regulation of MIF.
Intriguingly, we observed that HNSCC-derived MIF could bind to
membrane receptor CD74, CXCR2, and CXCR4 on the CD11b
+Gr-1+ myeloid cells and then activate p38/MAPK and PI3K/
AKT signaling pathways. Through these effects, MIF may not only
promote the chemotaxis of CD11b+Gr-1+ myeloid cells but also regu-
late the differentiation and pro-angiogenic function of CD11b+Gr-1+
myeloid cells. These results were consistent with recently published
paper in which Simpson et al. [37] demonstrated that MIF increased
the prevalence of CD11b+ myeloid cells within the tumor, leading to
promotion of 4T1 breast cancer growth and metastasis. These results
revealed novel functions of MIF on the regulation of CD11b+Gr-1+
myeloid cells, suggesting that MIF should be an attractive target for
therapeutic strategy in human HNSCC.
As a target gene of HIF-1α/2α, MIF stimulate the migration and
accumulation of CD11b+Gr-1+ myeloid cells. Intriguingly, HIF-1α/
2α KD did not significantly inhibit the CD11b+Gr-1+ myeloid
cell migration. It is possible that some other compensatory mech-
anisms exist after HIF-1α/2α KD in cancer cells. Our cytokine
array showed that HIF-1α/2α KD increased the expression of IL-6,
IL-8, CXCL10, and CCL5. Not incidentally, a previous study also
reported that HIF-1α KD resulted in increased levels of IL-6, IL-8,
and MCP-1 in human umbilical vein endothelial cells [38]. Since
the four cytokines were reported as NF-κB target genes [30], we
measured NF-κB activity using NF-κB luciferase reporter assay,
which revealed a significant increase of NF-κB activity after HIF-
1α/2α KD. Given the importance of IL-6 in the hypoxia-induced
migration of CD11b+Gr-1+ myeloid cells as our data has shown,
one explanation is that the increase of NF-κB activity further induced
IL-6 production, which mainly compensated for the loss of MIF after
HIF-1α/2α KD to regulate the migration of CD11b+Gr-1+ myeloid
cells (Figure 6).
To date, the direct association between NF-κB and HIF-1α has
been controversial. In neutrophil, NF-κB was demonstrated a hypoxia-
regulated and HIF-1α–dependent target [39]. However, NF-κB was
suggested as a critical transcriptional activator of HIF-1α in cultured
cells and in the liver and brain of hypoxic animals [40]. Contrarily,
NF-κB was also reported to block HIF-1α activity by direct com-
petition of p300 [41]. In addition, the increased HIF-1α stabilization
and transcriptional activity may be concurrent with decreased NF-κB
activity [42]. In this study, we show that HIF-1α/2α KD increased
NF-κB activity under hypoxia. However, whether HIF-1/2α KD
resulted in a shift of p300 from HIF-1α/2α to NF-κB has not yet been
well clarified and needs further investigation.
Although HIF-1α and HIF-2α have striking similarities in struc-
ture, function, and regulation, many lines of evidence suggest that
the roles of HIF-1α and HIF-2α in response to hypoxia vary among
cell types, and their biologic functions may be different [6,43]. In
this paper, however, we show that knocking down HIF-1α and
HIF-2α in HNSCC cells had similar effects on MIF level, NF-κB
activity, and migration of CD11b+Gr-1+ myeloid cells. Our results
revealed for the first time that HIF-2α plays equal important roles as
HIF-1α in the regulation of CD11b+Gr-1+ myeloid cell migration
and function.
We have shown that HNSCC cells admixed with CD11b+Gr-1+
myeloid cells had significantly higher volume and weight than that
with CD11b−Gr-1− cells. We further showed that combined KD of
HIF-1α/2α and NF-κB remarkably inhibited the recruitment of
CD11b+Gr-1+ myeloid cells in the xenograft tumor mass. This pro-
cess is accompanied by reduced tumor growth. These results suggest
that the inhibition of tumor growth by HIF-1α/2α and NF-κB KD
might be, at least partially, attributed to the decreased recruitment of
CD11b+Gr-1+ myeloid cells.
The majority of previous studies have been focusing on the immune
suppressive role of CD11b+Gr-1+ cells on growth of tumor [37,44]
Here, we investigated the contribution of CD11b+Gr-1+ cells to
HNSCC growth in immunodeficient nude mice. Our results suggest
that CD11b+Gr-1+ cells could promote the tumor growth due to
mechanisms other than antitumor immunity suppression. These results
are consistent with a recently published paper, in which Park et al. [45]
demonstrated that recruitment of CD11b+Gr-1+ cells to tumor tissue
contributed to prostate cancer angiogenesis and growth in an immuno-
deficient mouse model.
In conclusion, we demonstrated that, in hypoxic microenvi-
ronment of HNSCC, HIF-α/MIF axis regulates the migration,
differentiation, and pro-angiogenic function of CD11b+Gr-1+
myeloid cells that further contribute to the growth of tumor. When
HIF-1α/2α were artificially inhibited, NF-κB/IL-6 axis would
be increased to compensate for the loss of HIF-α/MIF. As such,
therapeutic outcome in terms of inhibiting CD11b+Gr-1+ myeloid
cells may benefit from combined targeting HIF-α/MIF and NF-κB/
IL-6 axes.
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Supplementary Materials and Methods
shRNA Cloning and Lentivirus Packaging
Lenti-X shRNA Expression System (Clontech) was used for the
shRNA-mediated inhibition of HIF-1α, HIF-2α, MIF, and IL-6
according to the manufacturer’s instruction. Short pairs of sense
and antisense DNA oligo encoding a sense-loop-antisense sequence
to target genes were synthesized by TAKARA (Dalian, China). The
shRNA target sequences for HIF-1α [1], HIF-2α [1], MIF [2], IL-6
[3], p65 [4], and negative control [1] have been described previously.
The complementary DNA oligos were annealed and cloned to the
BamHI/EcoRI-digested pLVX-shRNA1 vectors (Clontech). The recom-
binant vectors were purified and cotransfected with Lenti-X HT
Packaging Mix (Clontech) into HEK 293T packaging cells. The
virus-containing cell culture supernatants were collected 48 hours
after transfection, passed through a 0.45-μm filter, and stored at −80°C.
Tumor cells were transduced with recombinant lentivirus with 5 μg/ml
polybrene, and stable clones were selected using 1.0 μg/ml puromycin
24 hours after infection.
Cell Culture, Hypoxia Treatment, and
Lenti-X shRNA Transduction
Two human HNSCC cell lines Tca8113 and Cal-27 were obtained
from the State Key Laboratory of Oral Disease, Sichuan University.
Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY ) supple-
mented with 10% FBS (Hyclone, Logan, UT), 2 mM L-glutamine,
25 mM 2-(4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid
(Hepes), and 100 units/ml penicillin and 100 μg/ml streptomycin
in a humidified 5% CO2 atmosphere. The cells were cultured under
20% O2 (normoxia) or 1% O2 (hypoxia) conditions, balanced with
N2 in a three-gas incubator (Binder).
For siRNA transfection, cells were passaged and reseeded in six-
well plates at a density of 2 × 105 cells per well. Twenty-four hours
later, siRNA and Lipofectamine 2000 (Invitrogen) were diluted by
Opti-MEM I (Gibco), mixed, and then added to each well. The final
concentration of siRNA was 30 nM. The siRNA sequences for MIF
[2], IL-6 [3], PAI-1 [5], and ICAM-1 [6] used in this study have
been described previously.
Xenograft Tumor Model
The nude mice (6 weeks of age) were obtained from the Labora-
tory Animal Center of Sichuan University. Tumor cells were injected
s.c. (5 × 106 cells/200 μl PBS per mouse) on the back of nude mice.
The tumor size was monitored by measuring diameters using Vernier
caliper weekly and was calculated as πls2/6, where l = long side and
s = short side as described previously [7].
Flow Cytometric Analyses
Peripheral blood, spleens, and tumors were harvested, and single-cell
suspensions were prepared. Red cells were removed using ammonium
chloride lysis buffer. Freshly prepared cells (1 × 106) were incubated
at 4°C for 20 minutes with rabbit anti-mouse CD11b conjugated to
FITC, rat anti-mouse Gr-1 conjugated to PE, or rat anti-human
CD34–PE. Cells were washed with PBS, resuspended in 500 μl of 1%
paraformaldehyde, and analyzed on a Cytomics FC 500 MPL Flow
Cytometer (Beckman Coulter) using RXP software (Beckman Coulter).
Acquired data were analyzed using WinMDI 2.9 software.
To analyze the granulocytic (CD11b+Ly6GhighLy6Clow) and
monocytic (CD11b+Ly6GlowLy6Chigh) phenotypes, CD11b+Gr-1+
myeloid cells were stained with FITC-CD11b, PE-Ly6G, and
PerCp/Cy5.5-Ly6C. Fluorescence-labeled antibodies were purchased
from eBioscience. To analyze the CD34+ myeloid cell in the periph-
eral blood from patients and healthy volunteers, 1 ml of peripheral
blood was stained with FITC mouse anti-human CD34 (BD
Biosciences, San Jose, CA) at 4°C for 15 minutes. Red cells were
lysed by ammonium chloride lysis buffer. To analyze the expression
of CXCR2 and CXCR4 expression, CD11b+Gr-1+ myeloid cells
were stained with anti-mouse PerCp/Cy5.5-CXCR2 (BioLegend,
San Diego, CA), anti-mouse PE-CXCR4 (eBioscience), or isotype
control IgG. Samples were then analyzed on a Cytomics FC 500
MPL Flow Cytometer.
Immunofluorescence and Immunohistochemistry
Xenograft tumors were cut into two parts, one was placed in liquid
nitrogen and then frozen at −80°C, and the other was fixed by for-
malin and then embedded by paraffin. Frozen tissues were embedded
in optimal cutting temperature (Sakura Finetek, Tokyo, Japan),
frozen at −80°C, and cut (6 mm) in a cryostat (Leica Microsystem,
Bannockburn, IL). Frozen sections were dried at 20°C for 1 hour, fixed
in acetone at 4°C for 20 minutes, air-dried for 10 minutes at 20°C,
and incubated in 20% goat serum at 37°C for 30 minutes to block
nonspecific binding. To detect the CD11b+Gr-1+ myeloid cells,
slides were incubated overnight with rabbit anti-mouse CD11b
(1:50; NOVUS) and rat anti-mouse Gr-1 (1:50; eBioscience). The
second day, slides were washed and incubated for 1 hour with Alexa
Fluor 488 goat anti-rabbit IgG (1:500; Invitrogen) and DyLight 594
goat anti-rat IgG (1:500; Jackson). To detect the blood vessel, sections
were stained with primary rat anti-mouse CD31 (1:50; eBioscience)
and secondary DyLight 594 goat anti-rat IgG (Jackson). After washing,
coverslips were counterstained with 4′, 6-diamidino-2-phenylindole
(1 μg/μl) and examined by a Leica DMI6000 B fluorescence micro-
scope (Leica Microsystem) using Leica FW4000 V1.0 software.
MVD was assessed by a microscope as described previously [8].
The formalin-fixed paraffin-embedded sections were deparaf-
finized, rehydrated, endogenous peroxidase blocked, and antigen
retrieved. Then, slides were incubated at 37°C with rabbit anti-
human Ki-67 (1:500; Santa Cruz Biotechnology) for 2 hours. Slices
were then incubated with biotinylated goat anti-rabbit IgG or goat
anti-mouse IgG for 1 hour and streptavidin-peroxidase for 30 min-
utes. The 0.02% diaminobenzidine tetrahydrochloride was used as a
chromogen, and the slides were counterstained with hematoxylin.
The percentage of positive cells was estimated using an image analysis
system (Leica, Wetzlar, Germany).
CD11b+Gr-1+ Myeloid Cell Sorting
Spleens from mice were harvested, and single-cell suspensions
were prepared. Red cells were removed using ammonium chloride
lysis buffer. Cells were resuspended in PBS and incubated with
FITC-conjugated anti-mouse CD11b and PE-conjugated anti-mouse
Gr-1 (eBioscience). CD11b+Gr-1+ cells were sorted with a MoFlo
XDP cell sorter (Beckman Coulter) and cultured in RPMI 1640 with
10% FBS and 20 ng/ml GM-CSF.
Chemotaxis Assay
CD11b+Gr-1+ myeloid cells (5 × 104 cells per well) were seeded
onto the top chamber of a transwell insert (3 μM; Corning) and
were placed in a 24-well plate that contains cytokines or tumor-
conditioned media. The plates were incubated for 6 hours at 37°C
with 5% CO2. Migrated CD11b+Gr-1+ myeloid cells were stained
by 0.1% crystal violet, followed by cell lysis, and measurement of
optical density at 540 nm.
To investigate the role of interested cytokines on the in vitromigration
of CD11b+Gr-1+ myeloid cells, recombinant human IL-6 (1 μg/ml;
R&D Systems), rhMIF (1 μg/ml; R&D Systems), recombinant human
PAI-1 (1 μg/ml; Millipore, Billerica, MA), and recombinant human
ICAM-1 (0.5 μg/ml; eBioscience) were added to the lower well.
Cytokine Array and ELISA
Tumor cells were assigned to the following four groups: wild-type
cells cultured at 20% O2, wild-type cells cultured at 1% O2, HIF-1α
KD cells cultured at 1% O2, and HIF-2α KD cells cultured at 1%
O2. Cytokines in the supernatant were measured using Proteome
Profiler Human Cytokine Array Kit, Panel A (ARY005; R&D
Systems) according to the manufacturer’s protocol. Membranes were
scanned using a densitometer (GS-700; Bio-Rad Laboratories), and
quantification was performed using Quantity One 4.4.0 software.
Interested cytokines were further validated by ELISA using Quan-
tikine ELISA Kit (R&D Systems) following the manufacturer’s
instructions. The intensity of color was measured at 450 nm in a
microplate reader (Thermo). The concentration of protein in culture
media was determined in triplicate wells and was normalized to
standard curves generated for each set of samples assayed.
Quantitative Real-Time RT-PCR and Western Blot
Total RNA was isolated with TRIzol reagent (Invitrogen) and
reverse-transcribed using a RevertAid First-Strand cDNA Synthesis
Kit (Fermentas, Vilnius, Lithuania) with random hexamer primer.
PCR amplification of the cDNA template was performed using
Thunderbird SYBR qPCR mix (TOYOBO) on an ABI PRISM
7300 Sequence Detection System (Applied Biosystems). Reactions
were run in triplicate, and results were averaged. Each value was
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
the housekeeping gene to control. The sequences of PCR primers
for HIF-1α [8], HIF-2α [8], VEGF [8], PAI-1 [8], p65 [9], IL-6 [10],
MIF [11], and ICAM-1 [12] have been described previously.
Total proteins were isolated with a total protein extraction kit
(Keygen, Nanjing, China). Thirty micrograms of proteins was sepa-
rated on 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and transferred electrophoretically to polyvinylidene difluoride (PVDF)
membranes (Millipore, Boston, MA). Membranes were incubated for
2 hours, respectively, with mouse anti–HIF-1α (Abcam, Cambridge,
MA), rabbit anti–HIF-2α (Abcam), mouse anti–β-actin (Santa Cruz
Biotechnology), mouse anti-CD74 (M-B741, Santa Cruz Biotechnolo-
gy), rabbit anti-CXCR2 (H-100, Santa Cruz Biotechnology), rabbit
anti-CXCR4 (Abcam), rabbit anti–phospho-AKT (Ser473; Cell Sig-
naling Technology, Danvers, MA), rabbit anti-AKT (Cell Signaling
Technology), rabbit anti–phospho-p38 (Thr180/Tyr182; Cell Signal-
ing Technology), and rabbit anti-p38 (Cell Signaling Technology).
HRP-conjugated anti-mouse or anti-rabbit IgG was used as a sec-
ondary antibody (1:5000). Bands were scanned using a densitometer
(GS-700; Bio-Rad Laboratories), and quantification was performed
using Quantity One 4.4.0 software.
Luciferase Reporter Assay
Tumor cells (1 × 105/ml) were seeded into each well of a 12-well
plate, incubating at 37°C for 24 hours. Then, cells were transiently
transfected with 1 μg of pNF-κB–luc vector (Clontech) and 1 μg of
pRL-TK Vector (Promega) using the Lipofectamine 2000 (Invitrogen).
Six hours later, transfection media were changed, and cells were
cultured under either normoxia (21% O2) or hypoxia (1% O2) condi-
tions for an additional 24 hours. Cells were lysed in passive lysis buffer
(Promega) for 15 minutes, and 20 μl of lysates was assayed using the
Dual-Luciferase Reporter Assay System (Promega). Luciferase activity
was measured in a luminometer. Experiments were carried out in trip-
licate, and results are expressed as relative NF-κB activity compared
with controls after normalizing to Renilla luciferase activity.
Statistics
Comparisons of means among groups were analyzed by one-way
ANOVA, and mean tumor volume was analyzed by repeated measures
ANOVA. The Bonferroni test was further used to determine the differ-
ences between groups. The correlations between CD34+ myeloid cell
frequency and the clinical-pathologic characteristics of patients were
analyzed by Pearson χ2 test. All statistical analyses were done using
the SPSS 13.0. P < .05 was considered statistically significant.
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Figure W1. CD11b+Gr-1+ myeloid cells were sorted by FACS from spleens of tumor-bearing mice. The purity of post-sorting was
analyzed by flow cytometry.
Figure W2. Expression level of hypoxia-related cytokines measured by ELISA. 20% O2: Tumor cell cultured under normoxic condition;
1% O2: tumor cell cultured under hypoxic condition. Experiments were carried out in triplicate (*P < .05).
Figure W3. Knocking down efficiency of siRNAs targeting p65, IL-6,
MIF, sICAM-1, and PAI-1. The mRNA levels of these target genes
were measured by real-time PCR, and relative expression levels
were evaluated. Experiments were carried out in triplicate (*P< .05).
Figure W4. Gating strategy of flow cytometric analysis of granulocytic (CD11b+Ly6GhighLy6Clow) andmonocytic (CD11b+Ly6GlowLy6Chigh)
phenotypes in the xenograft tumors.
Figure W5. (A) Knocking down efficiency of HIF-1α and HIF-2α in the level of mRNA (left panel) and protein (right panel) was measured
by real-time PCR and Western blot, respectively. Experiments were carried out in triplicate (*P < .05). (B) The MIF protein levels in
supernatant of HIF-1α and HIF-2α KD tumor cells were measured by ELISA. Consistent with cytokine array data, MIF level was signif-
icantly decreased by knocking down HIF-1α and HIF-2α. (C) IL-6, IL-8, CXCL10, and CCL5 levels in the supernatant of tumor cells were
measured by ELISA. In accordance with the cytokine array data, HIF-1α and HIF-2α KD increased the level of IL-6, IL-8, CXCL10, and
CCL5. (D) Knocking down of p65 significantly inhibited the levels of IL-6, IL-8, CXCL10, and CCL5 measured by ELISA. Experiments were
carried out in triplicate (*P < .05).
Figure W6. Growth curve of xenograft tumor. Knocking down of
HIF-1α, HIF-2α, and NF-κB individually inhibited the growth of tumor
in comparison with the control. The growth of tumor was further
decreased by combined KDofHIF-1α/2α andNF-κB (n=5, *P< .05).
